
|Videos|January 16, 2014
Emerging Treatment Options for Patients With Kidney Cancer
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
Advertisement
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.
- New emerging treatment options are all trial-based
- There are newer antiangiogenic agents that are just as efficacious but generate less toxicity
- Researchers and oncologists are excited about immunotherapy for the treatment of kidney cancer
- New immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5








































